About Organogenesis
Organogenesis is a company based in Canton (United States) founded in 1985 was acquired by Avista Capital Partners in August 2018. Organogenesis has raised $30 million across 4 funding rounds from investors including Eastward Capital Partners, Massachusetts Life Sciences Center and Avista Capital Partners. The company has 869 employees as of December 31, 2024. Organogenesis has completed 1 acquisition, including Nutech Medical. Organogenesis offers products and services including PuraPlyAM, NuShield, Apligraf, and Affinity. Organogenesis operates in a competitive market with competitors including Tenaya Therapeutics, Athira Pharma, Ensoma, Orca Bio and Avita Medical, among others.
- Headquarter Canton, United States
- Employees 869 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Organogenesis Holdings Inc.
-
Annual Revenue
$482.04 M (USD)11.29as on Dec 31, 2024
-
Net Profit
$861 K (USD)-82.59as on Dec 31, 2024
-
EBITDA
$47.11 M (USD)18.45as on Dec 31, 2024
-
Total Equity Funding
$30 M (USD)
in 4 rounds
-
Latest Funding Round
$130 M (USD), Post-IPO
Nov 12, 2024
-
Investors
Eastward Capital Partners
& 2 more
-
Employee Count
869
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Avista Capital Partners
(Aug 17, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Organogenesis
Organogenesis is a publicly listed company on the NASDAQ with ticker symbol ORGO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Organogenesis
Organogenesis offers a comprehensive portfolio of products and services, including PuraPlyAM, NuShield, Apligraf, and Affinity.
Regenerative matrix for advanced wound healing treatments.
Biological graft for tissue repair in medical procedures.
Engineered skin substitute for chronic wound management.
Matrix for surgical and sports medicine applications.
People of Organogenesis
Unlock access to complete
Sales and Marketing
51 people
Software Development Team
26 people
Leadership Team
22 people
Product Management Team
13 people
Senior Team
7 people
QC Team
6 people
Operations Team
6 people
Customer Team
6 people
Unlock access to complete
Funding Insights of Organogenesis
Organogenesis has successfully raised a total of $30M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Organogenesis
Organogenesis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Eastward Capital Partners, Massachusetts Life Sciences Center and Avista Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm that does debt investment in the US
|
Locked | Locked | Locked | |
|
Life sciences innovation is supported through funding and programs.
|
Locked | Locked | Locked | |
|
Private equity investments are focused on the United States market.
|
Locked | Locked | Locked |
Investor details for Organogenesis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Organogenesis
Organogenesis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nutech Medical.
Investment portfolio details for Organogenesis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biologic and medical device company focusing on spinal and orthopedic surgical products
|
Locked | Locked | 1994 | Locked |
Complete acquisition details for Organogenesis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Organogenesis
Detailed financials for Organogenesis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Organogenesis Comparisons
Peer comparison for Organogenesis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Organogenesis
Organogenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Athira Pharma, Ensoma, Orca Bio and Avita Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed.
|
|
| Locked | Locked | Locked |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Products for regenerative and respiratory medicine are developed and distributed.
|
|
| Locked | Locked | Locked |
Cell and gene therapies are developed via an epigenomic platform.
|
Detailed competitors of Organogenesis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Organogenesis
Complete news archive for Organogenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Organogenesis
Organogenesis was founded in 1985 and raised its 1st funding round 24 years after it was founded.
Organogenesis is headquartered in Canton, United States. It is registered at Canton, Ohio, United States.
Gary S Gillheeney is the current CEO of Organogenesis.
Organogenesis is a funded company, having raised a total of $30M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Organogenesis is 869.
Annual revenue of Organogenesis is $482.04M as on Dec 31, 2024.
Organogenesis, an MIT spin-off, develops regenerative therapies for wound care. It has four approved products on the market. Apligraf is a living cell-based human skin substitute that is indicated for the treatment of venous leg ulcers and diabetic foot ulcers. Dermagraft is a human fibroblast-derived dermal substitute for diabetic foot ulcers.PuraPly is a collagen plus polyhexanide antimicrobial wound filling matrix. Additionally, Organogenesis also received FDA clearance for Gintuit, a scaffold product made of allogeneic cultured keratinocytes and fibroblasts, indicated for mucogingival conditions in adults.
Organogenesis's top competitors include Tenaya Therapeutics, Athira Pharma and Orca Bio.
Organogenesis offers PuraPlyAM, NuShield, Apligraf, and Affinity.
Yes, Organogenesis is publicly traded on NASDAQ under the ticker symbol ORGO.
Organogenesis has made 1 acquisition, including Nutech Medical.
Organogenesis has 3 investors. Key investors include Eastward Capital Partners, Massachusetts Life Sciences Center, and Avista Capital Partners.
The ticker symbol of Organogenesis is ORGO on NASDAQ.